TRITON2 Evaluation of rucaparib in patients with metastatic castrationresistant prostate cancer

TRITON2: Evaluation of rucaparib in patients with metastatic castration-resistant prostate cancer

09:40 EDT 26 Oct 2018 | ecancermedicalscience

DrJosep Piulats speaks with ecancer at ESMO 2018 in Munich about results from the TRITON2 study looking at the use of the PARP Inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer. Dr Piulats states that there are now over...

More From BioPortfolio on "TRITON2: Evaluation of rucaparib in patients with metastatic castration-resistant prostate cancer"